Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
DUBLIN, Ireland and TREVOSE, Pa., April 26, 2018 -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge’s management team on Thursday, May 10 at 8:30 a.m. ET to discuss the Company’s first quarter 2018 financial results and corporate highlights. The conference call will follow the anticipated release of the Company’s financial results earlier that day.
Event Details
Strongbridge will host a conference call on Thursday, May 10 at 8:30 a.m. ET. To access the live call, dial 844-285-7153 (domestic) or 478-219-0180 (international) with conference ID 4674956. The conference call will also be audio webcast from the Company’s website at www.strongbridgebio.com under the “Investor/Webcasts and Presentations” section. A replay of the call will be made available for one week following the conference call. To hear a replay of the call, dial 855-859-2056 (domestic) or 404-537-3406 (international) with conference ID 4674956.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's commercial portfolio within its rare neuromuscular and rare endocrine franchises includes KEVEYIS®(dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, and MACRILEN™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency. The Company’s rare endocrine franchise also includes a clinical-stage pipeline of therapies: RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
[email protected]
Investor Relations
United States:
Solebury Trout
Marcy Nanus
+1 646-378-2927
[email protected]
Europe:
First House
Geir Arne Drangeid
+47 913 10 458
[email protected]
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
